Retatrutide 10 mg

WHAT IS RETATRUTIDE 10 MG?

Retatrutide is a next-generation triple receptor agonist peptide that targets GLP-1, GIP, and glucagon receptors. This innovative compound is under investigation for its synergistic potential in promoting fat loss, appetite suppression, and metabolic regulation in research settings.

RESEARCH APPLICATIONS

• Obesity and bodyweight regulation models
• Enhanced insulin sensitivity and glucose control
• Lipid metabolism and thermogenic pathways
• Triple-receptor agonist comparative analysis

HOW RETATRUTIDE WORKS

By activating GLP-1, GIP, and glucagon receptors simultaneously, Retatrutide may improve glycemic control, enhance energy expenditure, and reduce appetite more effectively than single or dual agonist peptides. These properties make it a valuable tool in long-term metabolic research protocols.

RESEARCH DOSING PROTOCOL

• Common Research Dose: 2.5–10 mg per week
• Administration Route: Subcutaneous
• Research Duration: 6 to 12 weeks, depending on study design

STACKING OPTIONS IN METABOLIC RESEARCH

Retatrutide is often compared or studied alongside other weight management compounds:

• Tirzepatide – GIP/GLP-1 dual agonist
• Semaglutide – GLP-1 specific agonist
• Survodutide – GLP-1 + glucagon dual agonist

Lab Test Available

ORDERING & SHIPPING DETAILS

This peptide is available to order from our peptide source with U.S. domestic fulfillment. All peptides are intended for laboratory and research use only.

EXTERNAL REFERENCE

Learn more via Retatrutide on PubChem.

FAQ